Mithra and Mediner Sign LSA for Tibelia® in Hungary

/in /by

Mithra grants exclusive license for Tibelia® to Mediner for commercialization in Hungary Tibelia® is currently marketed in a 8 countries through existing license and supply agreements Further Tibelia® launches anticipated in 2018 Liège, Belgium, 13 July 2018 –  Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces an exclusive license and supply […]

Read more →

Mithra and Orifarm Sign LSA for Vaginal Contraception Ring in Denmark

/in , /by

Mithra grants exclusive license for vaginal contraception ring to Orifarm for commercialization in Denmark/li> Agreement follows MyringTM licenses closed with Mayne Pharma, Gynial, Adamed and Alvogen for the US, Austria, the Czech Republic and Russia, respectively Vaginal ring shall be manufactured at Mithra CDMO Liège, Belgium, 21 June 2018 –  Mithra (Euronext Brussels: MITRA), a […]

Read more →

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

/in /by

Liège, Belgium, 8 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today presents its Phase IIb results for Donesta® at the International Menopause Society’s 16th World Congress on menopause (Vancouver, Canada). Donesta® is Mithra’s next-generation hormone therapy (HT) product candidate with oral administration of Estetrol (E4) for the treatment of Vasomotor […]

Read more →

Information on the total number of voting rights (denominator)

/in , /by

Liège, Belgium, 05 June 2018 [5:45 pm CET] – Regulated information – In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 2,672,414 new shares on 4 June 2018 in the framework of the private placement announced […]

Read more →

Mithra Signs Binding Heads of Terms for Commercialization of Estelle® in South Korea with Women’s Health Specialist Hyundai pharm

/in , /by

Mithra eligible for milestone payments, recurring revenues and further sales-related royalty payments, with production of Estelle® for the South Korean market at the Mithra CDMO With Estelle®, Hyundai Pharm aims to further expand its growing footprint in Women’s Health Liège, Belgium, 5 June 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, […]

Read more →

Mithra Successfully Raises EUR 77.5 Million

/in , /by

Liège, Belgium, 31 May 2018, 07:00 CET – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces that it has successfully raised EUR 77.5 million in gross proceeds by means of a private placement of 2,672,414 new shares through an accelerated bookbuild offering (the “Private Placement“).

Read more →

Mithra Announces Further Positive Phase IIb Donesta® Efficacy and Safety Data

/in , /by

Further analysis of the E4 Relief dose-finding study shows a statistically significant reduction in the severity of VMS (hot flushes) at the optimal minimum dose (15 mg  E4) Data reinforce the previously announced positive Phase IIb Donesta® results, demonstrating a meaningful and statistically significant reduction in the frequency of VMS Encouraging cardiovascular safety profile further […]

Read more →

Mithra Launches Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering

/in , /by

Liège, Belgium, 30 May 2018, 16:05 CET – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces the launch of a capital increase of approximately EUR 60 million by means of a private placement via an accelerated bookbuild offering (the “Private Placement”), with the possibility to increase the […]

Read more →

Update on Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Opportunity

/in , /by

Liège, Belgium, 28 May 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today provides an update on the progress made with its vaginal contraception ring, Myring™ for the US market.

Read more →

Mithra Announces Injectable Contrat with Midas Pharma

/in , /by

Mithra closes contract with Midas Pharma for development and potential manufacturing of sterile injectable Strong validation by reputable partner of know-how and capabilities of Mithra CDMO Liège, Belgium, 16 May 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces a contract with Midas Pharma for the development of a sterile […]

Read more →